Pharma
Commented by Stefan Feulner on August 1st, 2023 | 09:00 CEST
Biogen, Cardiol Therapeutics, Evotec - The acquisition wave is rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions for unmet medical needs. At the same time, despite an increase in value in recent months, acquisition targets are still attractively valued due to the sell-off over the past year.
Read
Commented by Armin Schulz on July 31st, 2023 | 09:20 CEST
Bayer, Defense Metals, Alibaba - Stocks with doubling potential
Discovering stocks with high growth potential during difficult market periods is a challenging task. While there is no guarantee that a stock will double in value, certain factors can help identify companies with promising growth prospects. One effective approach is to focus on industries that offer growth opportunities even in adverse market conditions. Otherwise, examining fundamentals and ensuring the story fits the current spirit of the times is advisable. We have selected three possible doubling candidates.
Read
Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST
Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row
While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.
Read
Commented by Juliane Zielonka on July 21st, 2023 | 07:20 CEST
BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI
There are exciting developments in the biotech industry. Thanks to innovative AI technologies, companies like BioNxt Solutions bionxt.com/investors can analyze medical data faster and develop an innovative medical patch that provides Parkinson's patients with faster symptom relief. This patch carries the active ingredient rotigotine and has enormous market opportunities worldwide. Blockbuster-level market opportunities are emerging at Morphosys with regard to its compound pelabresib for the treatment of a rare form of blood cancer. The Phase III trial is expected to deliver results earlier than expected, and analysts see promising opportunities for the drug. According to a study by Bristol Myers Squibb, about 1.85 million new cases of blood cancer are expected worldwide in 2040. Deutsche Bank rated the stock "hold," driving the price up 4.9% this week. Also pushing upward is Palantir. The US company is getting into the drone business thanks to a partnership with Canada's Airmatrix.
Read
Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST
Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?
In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.
Read
Commented by Juliane Zielonka on July 13th, 2023 | 07:40 CEST
Defence Therapeutics, Bayer AG, Rheinmetall: Patents, price jump and billions of euros
The global biotechnology market is estimated to grow at a CAGR of 12.8% from 2023 to 2030. This has prompted Defence Therapeutics to secure numerous patents for their innovative platform technology ACCUM™. The platform is the linchpin for therapies in the fight against globally prevalent cancers such as lung, breast, and pancreatic cancer. Defence Therapeutics focuses on strengthening the body's immune system to defend against evil invaders. Cancer is also a topic at Bayer AG. The share price jumps as rumors circulate that the Group intends to divest its agricultural division - including Monsanto and the weedkiller suspected of causing cancer. Rheinmetall can report a further plus. Both the German and Dutch armies are ordering airborne vehicles worth billions. Whether these orders are intended solely for Ukraine will become clearer as the latest news unfolds regarding NATO's activities.
Read
Commented by Nico Popp on July 11th, 2023 | 07:30 CEST
Returns thanks to e-prescription and co.: Redcare Pharmacy, BB Biotech, Cardiol Therapeutics
There are attractive returns to be had in the healthcare sector. Innovative approaches around data and biotechnology are particularly promising, according to Daniel Matviyenko, Portfolio Manager of Healthcare Strategies at Jennison Associates. But what does this innovation look like in concrete terms? And how can investors invest? We highlight the healthcare industry using three companies as examples, with a special focus on opportunities in select individual stocks.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Juliane Zielonka on June 28th, 2023 | 07:40 CEST
Cardiol Therapeutics, Bayer, BASF - Sensational breakthroughs in medicine and sustainability
A study in the JACC journal shows that cardiovascular risk factors and diseases will increase sharply in the US. Ischemic heart disease is projected to increase by 31.1%, heart failure by 33.0% and myocardial infarction by 30.1%. Cardiol Therapeutics, a Canadian company specializing in cardiovascular diseases, is thus rapidly gaining in importance. Bayer goes AI and partners for the first time with a Swiss hospital for a digital solution that supports radiologists in diagnosis and treatment. BASF invests with its venture arm in the Swiss startup DePoly, which has developed an innovative chemical recycling technology. Discover the sustainable solution behind this investment here.
Read
Commented by Fabian Lorenz on June 21st, 2023 | 08:40 CEST
Biotech comeback! Profit with BioNTech, Morphosys and BioNxt Solutions
Biotech shares have not been among the favourites on the stock market in recent months. After the Corona hype, they were overshadowed by BigTech and especially AI. Sartorius, BioNTech and Co. have corrected strongly. But in the meantime, there are strong signs of a comeback - led by Morphosys. The share of the German biotech veteran has doubled since the beginning of April. MediGene and Evotec have also recorded price jumps. Are BioNTech and BioNxt Solutions next? Morphosys also continues to be praised by analysts. But Goldman Sachs wants to end the party.
Read